Does cost-effectiveness play a role in clinical trials?

Dermatologic Therapy

Volumn 20, Issue 2, 2007, Pages 110-119

  Steele, Tace ^a   Pawaskar, Manjiri ^b   Balkrishnan, Rajesh ^b   Fleischer, Alan ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Atopic dermatitis; Health services research; Pharmacoeconomics; Psoriasis; Skin disease

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; METHOTREXATE; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; BASAL CELL CARCINOMA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG INDUSTRY; EMOTIONALITY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MEDICAL CARE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHOTOTHERAPY; PHYSICIAN; PRODUCTIVITY; PSORIASIS; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

CARCINOMA, BASAL CELL; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DERMATITIS, ATOPIC; ECONOMICS, PHARMACEUTICAL; HEALTH SERVICES RESEARCH; HUMANS; PSORIASIS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 34249293724     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00119.x     Document Type: Review

References (27)

1. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford, UK : Oxford Medical Publications, 1987.
2. Johnson NE, Nash DB. The role of pharmacoeconomics in outcomes management. Chicago : American Hospital Publishing, 1996.
3. Spikler B (ed). Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia, PA : Lippincott-Raven, 1996.
4. Laaser U, Roccella EJ, Rosenfeld JB, Wenzel H. Costs and benefits in health care and prevention. Berlin, Germany : Springer-Verlag, 1990.
5. Riegelman RK. The measures of medicine: benefits, harms, and costs. Cambridge, MA : Blackwell Science, 1995.
6. Max W, Rice DP, Sung HY, Zhang X, Miller L. The economic burden of smoking in California. Tob Control 2004 : 13 : 264 267.
7. Agency for Health Care Policy and Research. Study of Patient Outcomes Associated with Pharmaceutical Therapy. AHCPR grant announcement. Washington, DC : US Dept of Health and Human Services, Public Health Service 1992.
8. Meyer H. The pills that ate your profits. Hosp Health Netw 1998 : 72 : 18 22.
9. National Coalition on Health Care. Health insurance costs: facts on the cost of health care 2004. Available at: http://www.nchc.org/facts/costs.shtml. Accessed March 20, 2007.
10. Thorpe KE, Florence CS, Joski P. Which medical conditions account for the rise in health care spending? Health Aff (Millwood) 2004 Suppl 437 445.
11. Newhouse JP. An iconoclastic view of health cost containment. Health Aff (Millwood) 1993 : 12 (Suppl 152 171.
12. The Henry J. Kaiser Family Foundation. Employee Health Benefits: 2006 Annual Survey. 26 September 2006. http://www.kff.org/insurance/7315/index.cfm.
13. Venkat AP, Scheinfeld NS, Kulkarni AS, Balkrishnan R, Feldman SR. Health insurance benefit limits: general concepts and the potential impact on dermatologic treatment. J Am Acad Dermatol 2005 : 53 : 140 142.
14. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol 1993 : 28 : 422 425.
15. Schwartz JS, Vanscoy GJ, Lee TH. Healthcare economics: the new tool for clinical decision making. Center for Continuing Education in Health Sciences, University of Pittsburgh, 1995.
16. Dehkharghani S, Bible J, Chen JG, Feldman SR, Fleischer AB Jr. The economic burden of skin disease in the United States. J Am Acad Dermatol 2003 : 48 : 592 599.
17. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases 2004: a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006 : 55 : 490 500.
18. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD. Psoriasis. J Am Acad Dermatol 1984 : 11 : 937 947.
19. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002 : 46 : 361 370.
20. Arikian SR, Einarson TR. The annual cost of psoriasis. J Am Acad Dermatol 1994 : 30 : 1047 1048.
21. Zug KA, Littenberg B, Baughman RD, et al. Assessing the preferences of patients with psoriasis. A quantitative utility approach. Arch Dermatol 1995 : 131 : 561 568.
22. Chen S, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs. Goeckerman therapy for psoriasis. Arch Dermatol 1998 : 34 : 1602 1608.
23. Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. J Am Acad Dermatol 2002 : 46 : 242 250.
24. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003 : 48 : 553 563.
25. Ellis CN, Kahler KH, Grueger J, Chang J. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol 2006 : 7 : 133 139.
26. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006 : 154 : 1137 1146.
27. Essers BA, Dirksen CD, Nieman FH, et al. Cost-effectiveness of Mohs micrographic surgery vs. surgical excision for basal cell carcinoma of the face. Arch Dermatol 2006 : 142 : 187 194.